LCO No. 833 1 of 2
General Assembly Proposed Bill No. 5485
January Session, 2025
LCO No. 833
Referred to Committee on INSURANCE AND REAL ESTATE
Introduced by:
REP. LUXENBERG, 12th Dist.
AN ACT ESTABLISHING A CAPTIVE INSURANCE COMPANY TO
ADMINISTER A BULK PURCHASE AND DISTRIBUTION OF
GLUCAGON-LIKE PEPTIDE-1 PRESCRIPTION DRUGS TO
QUALIFYING INDIVIDUALS IN THIS STATE TO TREAT OBESITY.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:
That title 38a of the general statutes be amended to establish a captive 1
insurance company, which shall be supported by the appropriation of 2
the sum of ten million dollars to said captive insurance company, from 3
the General Fund, for the fiscal year ending June 30, 2026, for the 4
purpose of (1) bulk purchasing glucagon-like peptide-1 receptor 5
antagonist prescription drugs from drug manufacturers, and (2) 6
distributing such prescription drugs to covered persons in this state who 7
satisfy a means-tested qualification process and demonstrate an 8
inability to obtain such prescription drugs from such covered person's 9
health insurer to treat obesity. 10
Statement of Purpose:
To establish a captive insurance company, which shall be supported by
the appropriation of the sum of ten million dollars to said captive
insurance company, from the General Fund, for the fiscal year ending Proposed Bill No. 5485
LCO No. 833 2 of 2
June 30, 2026, for the purpose of (1) bulk purchasing glucagon-like
peptide-1 receptor antagonist prescription drugs from drug
manufacturers, and (2) distributing such prescription drugs to covered
persons in this state who satisfy a means-tested qualification process
and demonstrate an inability to obtain such prescription drugs from
such covered person's health insurer to treat obesity.